ES2150897T3 - Procedimiento de fabricacion recombinante de las proteinas derivadas de hiv-2 y cultivo celular que expresa proteinas de hiv-2. - Google Patents

Procedimiento de fabricacion recombinante de las proteinas derivadas de hiv-2 y cultivo celular que expresa proteinas de hiv-2.

Info

Publication number
ES2150897T3
ES2150897T3 ES89101328T ES89101328T ES2150897T3 ES 2150897 T3 ES2150897 T3 ES 2150897T3 ES 89101328 T ES89101328 T ES 89101328T ES 89101328 T ES89101328 T ES 89101328T ES 2150897 T3 ES2150897 T3 ES 2150897T3
Authority
ES
Spain
Prior art keywords
hiv
proteins
cell culture
manufacturing procedure
expresses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89101328T
Other languages
English (en)
Inventor
Luc Montagnier
Solange Chamaret
Denise Guetard
Marc Alizon
Francois Clavel
Mireille Guyader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27576220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2150897(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8600911A external-priority patent/FR2593190B1/fr
Priority claimed from FR8600910A external-priority patent/FR2593189B1/fr
Priority claimed from FR8601635A external-priority patent/FR2593922B1/fr
Priority claimed from FR8601985A external-priority patent/FR2594229B1/fr
Priority claimed from US06/835,228 external-priority patent/US4839288A/en
Priority claimed from FR8603881A external-priority patent/FR2596063B1/fr
Priority claimed from FR8604215A external-priority patent/FR2597500B1/fr
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Publication of ES2150897T3 publication Critical patent/ES2150897T3/es
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)

Abstract

LA INVENCION SE REFIERE A UNA NUEVA VARIEDAD DE RETROVIRUS, DENOMINADOS HIV - 2, CUYAS MUESTRAS HAN SIDO DEPOSITADAS EN ECACC BAJO LOS NUMEROS 87.01 1001 Y 87.01 1002 Y EN NCIB BAJO LOS NUMEROS 12398 Y 12399. SE REFIERE TAMBIEN A LOS ANTIGENOS SUSCEPTIBLES DE OBTENERSE A PARTIR DE ESTE VIRUS, EN PARTICULAR DE PROTEINAS P12, P16, P26 Y GP140. ESTOS DIFERENTES ANTIGENOS SON APLICABLES AL DIAGNOSTICVO DE LA ENFERMEDAD, PARTICULARMENTE POR LA PUESTA EN CONTACTO CON UN SERUM DE LA ENFERMEDAD DEL QUE EL DIAGNOSTICO DEBE SER EFECTUADO. SE REFIERE A COMPOSICIONES INMUNOGENICAS CONTENIENDO MAS PARTICULARMENTE LA GLICOPROTEINA SP140. SE REFIERE TAMBIEN A SECUENCIAS NUCLEOTIDICAS, UTILIZABLES PARTICULARMENTE COMO SONDAS DE HIBRIDACION, DERIVADOS DEL ARN DE HIV -2.
ES89101328T 1986-01-22 1987-01-22 Procedimiento de fabricacion recombinante de las proteinas derivadas de hiv-2 y cultivo celular que expresa proteinas de hiv-2. Expired - Lifetime ES2150897T3 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
FR8600910A FR2593189B1 (fr) 1986-01-22 1986-01-22 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8600911A FR2593190B1 (fr) 1986-01-22 1986-01-22 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8601635A FR2593922B1 (fr) 1986-02-06 1986-02-06 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8601985A FR2594229B1 (fr) 1986-02-13 1986-02-13 Nouveau retrovirus du type lav-ii susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
US06/835,228 US4839288A (en) 1986-01-22 1986-03-03 Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
FR8603881A FR2596063B1 (fr) 1986-03-18 1986-03-18 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR8604215A FR2597500B1 (fr) 1986-03-24 1986-03-24 Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
US91608086A 1986-10-06 1986-10-06
US93318486A 1986-11-21 1986-11-21

Publications (1)

Publication Number Publication Date
ES2150897T3 true ES2150897T3 (es) 2000-12-16

Family

ID=27576220

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89101328T Expired - Lifetime ES2150897T3 (es) 1986-01-22 1987-01-22 Procedimiento de fabricacion recombinante de las proteinas derivadas de hiv-2 y cultivo celular que expresa proteinas de hiv-2.

Country Status (15)

Country Link
EP (2) EP0320495B1 (es)
JP (7) JP2611106B2 (es)
AR (1) AR243931A1 (es)
AT (2) ATE47725T1 (es)
AU (1) AU601397B2 (es)
DE (3) DE3760912D1 (es)
DK (2) DK175959B1 (es)
ES (1) ES2150897T3 (es)
GR (3) GR880300056T1 (es)
HK (1) HK62091A (es)
NZ (1) NZ219024A (es)
OA (1) OA08468A (es)
PT (1) PT84182B (es)
SG (1) SG28591G (es)
WO (1) WO1987004459A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249611A4 (en) * 1985-11-14 1988-04-26 Harvard College T-LYMPHOTROPHIC VIRUS.
EP0750041B1 (fr) * 1987-01-16 2008-12-10 Institut Pasteur Séquences de nucléotides de HIV-2 et SIV-1
DE3855947T2 (de) * 1987-01-16 1997-12-11 Pasteur Institut Peptide mit den immunologischen Eigenschaften von HIV-2
AU620804B2 (en) * 1987-03-23 1992-02-27 Hiver Limited Novel vaccines
SE8701765L (sv) * 1987-04-28 1988-10-29 Statens Bakteriologiska Lab Analysmetod och medel foer denna
US4812556A (en) * 1987-05-18 1989-03-14 Virovahl Synthetic peptide antigen for the detection of HIV-2 infection
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
US5780038A (en) * 1987-11-16 1998-07-14 Roche Diagnostic Systems, Inc. HIV-2 envelope polypeptides
ATE87487T1 (de) * 1987-11-16 1993-04-15 Hoffmann La Roche Rekombinante hiv-2 polypeptide.
WO1989006276A2 (en) * 1988-01-08 1989-07-13 Dpz Deutsches Primatenzentrum Gesellschaft Mbh Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
US6210874B1 (en) 1988-01-27 2001-04-03 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
WO1989009815A1 (en) * 1988-04-04 1989-10-19 Research Corporation Technologies, Inc. Novel virus of the hiv-2 family and methods of detection therefor
US6197496B1 (en) 1988-06-09 2001-03-06 Institut Pasteur Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80
EP1369427A3 (en) * 1988-06-09 2004-05-12 Innogenetics N.V. HIV-3 retrovirus strains and their use
US5208321A (en) 1988-06-09 1993-05-04 Institut Pasteur HIV-2 transmembrane glycoprotein homodimer (GP 80)
EP0345559A3 (en) * 1988-06-10 1990-07-11 Abbott Laboratories Hiv-2 variants
DE68927025T2 (de) † 1988-06-14 1997-03-27 Qiagen Gmbh HIV-2-Virusvarianten
ATE136789T1 (de) * 1989-05-12 1996-05-15 Pasteur Institut Antigene eines transmembranen hüllenglycoproteins eines menschlichen retrovirus des typs hiv-2 und immunologisch verwandte antigene
FR2646854A1 (fr) * 1989-05-12 1990-11-16 Pasteur Institut Antigenes de la glycoproteine transmembranaire d'enveloppe d'un retrovirus humain du type hiv-2 antigenes presentant avec eux une parente immunologique
DE68925202T2 (de) * 1989-05-31 1996-06-05 Pasteur Institut HIV-2-EHO-Retrovirus-Proteine und -Glycoproteine, Antikörper gegen sie, Verwendung für diagnostische Zwecke
ES2275451T3 (es) * 1989-06-02 2009-02-16 Institut Pasteur Secuencias nucleotidicas procedentes del genoma de los retrovirus del tipo vih-1,vih-2 y siv, y sus aplicaciones especialmente para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones debidas a estos virus.
FR2647810B1 (fr) * 1989-06-02 1994-07-22 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
FR2647809B1 (fr) * 1989-06-02 1991-09-20 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
US7022814B1 (en) 1992-01-21 2006-04-04 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
FR2657016B1 (fr) * 1990-01-16 1995-08-25 Clonatec Sa Peptides derivant de la glycoproteine d'enveloppe du virus-hiv-2, leurs applications a la detection d'une infection due a ce virus et a la vaccination contre le sida.
EP0438332B1 (fr) * 1990-01-16 1998-04-08 Orgenics Ltd. Peptides dérivant de la glycoprotéine d'enveloppe de virus HIV, leurs applications à la détection d'une infection due à ces virus et à la vaccination contre le SIDA
ATE105857T1 (de) 1990-06-15 1994-06-15 Innogenetics Nv Siv cpz-ant retrovirus und seine anwendungen.
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
CA2107732C (en) * 1992-10-06 2003-04-08 Lutz G. Gurtler Retrovirus from the hiv group and its use
DE4233646C2 (de) * 1992-10-06 2003-10-23 Dade Behring Marburg Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US5962665A (en) * 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
FR2767337B1 (fr) 1997-08-14 2002-07-05 Pasteur Institut Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose
CA2422956C (en) 2000-10-23 2010-10-19 Gen-Probe Incorporated Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2)
CA2547750C (en) 2003-12-19 2014-04-08 Gen-Probe Incorporated Compositions, methods and kits for detecting the nucleic acids of hiv-1 and hiv-2
JP6721772B1 (ja) 2019-03-26 2020-07-15 斉藤　幹雄 清掃装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652599A (en) * 1984-04-23 1987-03-24 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS using permissive cells
ATE250083T1 (de) * 1984-10-18 2003-10-15 Pasteur Institut Lav-antigene und -peptide
US4600413A (en) * 1984-12-10 1986-07-15 Sundstrand Corporation Centrifugal deaerator and pump
JP3105581B2 (ja) * 1991-07-03 2000-11-06 内橋エステック株式会社 面状温度ヒュ−ズ

Also Published As

Publication number Publication date
JP2771519B2 (ja) 1998-07-02
DE239425T1 (de) 1988-06-30
DK176253B1 (da) 2007-04-30
JP2931294B2 (ja) 1999-08-09
JP2735521B2 (ja) 1998-04-02
EP0239425A1 (fr) 1987-09-30
NZ219024A (en) 1990-04-26
ATE47725T1 (de) 1989-11-15
PT84182A (pt) 1987-02-01
EP0239425B1 (fr) 1989-11-02
JPH0975092A (ja) 1997-03-25
GR880300056T1 (en) 1988-10-18
PT84182B (pt) 1989-09-14
DE3752319T2 (de) 2001-03-15
AU601397B2 (en) 1990-09-13
JP2801162B2 (ja) 1998-09-21
DK200500170A (da) 2005-02-04
JPH08113598A (ja) 1996-05-07
AR243931A1 (es) 1993-09-30
DK175959B1 (da) 2005-08-29
JPH06113833A (ja) 1994-04-26
JPH0937778A (ja) 1997-02-10
GR3034708T3 (en) 2001-01-31
DE3752319D1 (de) 2000-09-07
AU6891187A (en) 1987-08-14
ATE195148T1 (de) 2000-08-15
DK493487A (da) 1987-11-17
DE3760912D1 (en) 1989-12-07
HK62091A (en) 1991-08-16
EP0320495A1 (fr) 1989-06-14
OA08468A (fr) 1988-07-29
JPH1118768A (ja) 1999-01-26
JPH08275783A (ja) 1996-10-22
WO1987004459A1 (fr) 1987-07-30
JPH07233196A (ja) 1995-09-05
JP2874846B2 (ja) 1999-03-24
SG28591G (en) 1993-02-19
GR3001096T3 (en) 1992-04-17
JP2611106B2 (ja) 1997-05-21
DK493487D0 (da) 1987-09-21
EP0320495B1 (fr) 2000-08-02

Similar Documents

Publication Publication Date Title
ES2150897T3 (es) Procedimiento de fabricacion recombinante de las proteinas derivadas de hiv-2 y cultivo celular que expresa proteinas de hiv-2.
ES2262166T3 (es) Sintesis de proteinas o polipeptidos codificados por un secuencia nucleotidica vih-1, vih-2 o siv.
Ruprecht et al. Endogenous retroviruses: endogenous retroviruses and cancer
Villarreal et al. On viruses, sex, and motherhood
Poignard et al. Antibody neutralization of HIV-1
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
US5480967A (en) HIV-1 core protein fragments
ES2052478T1 (es) Particulas retrovirales no replicantes producidas de forma recombinante empleadas como agentes antivirales e inmunogenos.
DK605987D0 (da) Bestemte dna-sekvenser afledt af et papillomavirus-genom, deres anvendelse til in vitro diagnoseformaal og fremstilling af antigeniske praeparater
OA10814A (en) Mixture of recombinant vaccinia vectors as polyenvvaccines for hiv
DK513388D0 (da) Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2
CO5560591A2 (es) Vacunas de adn optimizadas por el codon vih-gag
ES2140380T3 (es) Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas.
DE60026199T2 (de) Synthetische Gene für gagpol und deren Verwendungen
CU23235A1 (es) POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
EP0412766B1 (en) Peptide fragments of HIV
US20070172930A1 (en) process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype isolates, their genes and modifications and derivatives thereof
US20040142449A1 (en) Replication-competent molecular clones of porcine endogenous retrovirus class a and class b derived from pig and human cells
US7713530B2 (en) HIV-1 subtype isolate regulatory/accessory genes, and modification and derivatives thereof
Koya et al. Establishment of a seronegative human T-cell leukemia virus type 1 (HTLV-1) carrier state in rats inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially expressing Tax
Saitoh et al. A unique monoclonal antibody that recognizes mature p17 of HIV-1 but not its precursor
JP4344805B2 (ja) 遺伝子組換えワクシニアウイルスワクチン
CA2057040A1 (en) Induction of protection against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
Fultz et al. Isolation of sooty mangabey simian T-cell leukemia virus type I [STLV-I (sm)] and characterization of a mangabey T-cell line coinfected with STLV-I (sm) and simian immunodeficiency virus SIVsmmPBj14
Vogt et al. Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 320495

Country of ref document: ES